Insulin Delivery Devices Market: Growth, Size, Share, and Trends

7500+ companies worldwide approach us every year for their revenue growth initiatives
Global top 2000 strategist rely on us for their growth strategies.
80% of fortune 2000 companies rely on our research to identify new revenue sources.
30000 High Growth Opportunities
95% renewal rate
KNOW MORE
  1. HOME
  2. Top Market Reports
  3. Insulin Delivery Devices Market

Insulin Delivery Devices Market by Type (Insulin Pens [Reusable, Disposable], Insulin Pumps (Tethered, Tubeless), Insulin Syringes, Insulin Pen Needles (Standard, Safety)), End User (Hospitals & Clinics, Patients/Homecare) - Global Forecast to 2028

FREE BROCHURE FREE SAMPLE REPORT
Report Code: MD 5192 Jul, 2023, by marketsandmarkets.com

Market Growth Outlook Summary

The global insulin delivery devices market growth forecasted to transform from $30.8 billion in 2023 to $46.2 billion by 2028, driven by a CAGR of 8.5%. Key growth drivers include the rising prevalence of diabetes, government support, and technological advancements. However, high costs and limited reimbursement in developing regions are expected to limit growth. Notable trends include the increasing use of insulin pens and pumps, particularly in home care settings. North America leads the market, driven by high healthcare expenditure and favorable reimbursement policies. Major players include Embecta Corp., Novo Nordisk, Medtronic, Sanofi, Eli Lilly, and others, who are expanding their operations and launching innovative products. Key challenges involve the high cost of devices and issues like needlestick injuries, while opportunities lie in the rising global healthcare expenditure on diabetes care.

Insulin Delivery Devices Market Trends

Insulin Delivery Devices Market

To know about the assumptions considered for the study, Request for Free Sample Report

Insulin Delivery Devices Market

Insulin Delivery Devices Market Dynamics

Driver: Growing prevalence of diabetic population

Diabetes is one of the most common non-communicable diseases across the globe. According to the World Health Organization, 422 million people worldwide have diabetes, and 1.5 million deaths are directly attributes to diabetes each year. Among the seven IDF regions, North America and Caribbean has the highest prevalence of diabetes (13.3%), followed by the Middle East and North Africa. Moreover, modern lifestyle characterized by reduced physical activities, rapid urbanization associated with changes in dietary patterns, reduced physical activities, increased consumption of processed foods, and genetic factors have contributes to the increased prevalence of diabetes.

Restraint: High cost and lack of reimbursement in developing countries

The cost of insulin delivery devices, such as smartphone connected insulin pumps, is approximately USD 4,500-6500. Moreover the average selling price of sensor-based continuous glucose monitors is USD 1,000- 1,400. Thus, due to high initial cost and the frequent use of associated consumables has put the technology advanced insulin delivery devices out of reach for large portion of users, particularly those n developing countries with an unfavourable reimbursement scenario.

Opportunity: Increasing healthcare expenditure on diabetes care

The increase in global health expenditure due to diabetes has been considerable, growing from USD 232 billion in 2007 to USD 966 billion in 2021 for adults aged 20–79 years. This represents a 316% increase over 15 years. Part of this increase can be attributed to improved data quality. The direct costs of diabetes are expected to continue to grow. The IDF estimates that total diabetes-related health expenditure will reach USD 1.03 trillion by 2030 and USD 1.05 trillion by 2045 (Source: IDF Atlas 2021). The North America and Caribbean region has the highest diabetes-related health expenditure per adult with diabetes (USD 8,209), followed by the Europe region (USD 3,086), South and Central America region (USD 2,190), and WP region (USD 1,204). This figure is USD 465 per person with diabetes in the Middle East and North Africa region, USD 547 in the Africa region, and USD 112 in the Southeast Asia region. Expenditure due to diabetes has a substantial impact on total health expenditure worldwide, representing 11.5% of the total global health spending. Considering the increasing diabetes-related health expenditure in emerging countries, many insulin delivery devices manufacturers are focusing on expanding their business in these markets to capitalize on new opportunities.

Challenge: Needlestick injuries and misuse of injection pens

The lack of proper education and training for the use of new delivery devices such as injection pen leads threatens the safety of the staff and patients. Such practices affects the adoption of injection pens in hospital settings. For instance, the National Reporting and Learning System (NRLS, UK) reported about 56 incidents associated with withdrawing insulin from insulin pens or refill cartridges between January 2013 and June 2019. In addition, the strength of insulin in the injection pen varies; thus, this poses the risk of overdose if the dose strength is not taken into consideration. However, training and education for the proper use of insulin injection pens and government regulations, along with the product development, are likely to overcome the challenge.

Insulin delivery devices market Ecosystem Map

Insulin Delivery Devices Market Ecosystem

By type, the insulin pen segment is projected to lead the market of the insulin delivery devices industry in 2023.

The large share of this segment of the insulin delivery devices market is primary attributed to improved dosage accuracy and medication adherence, increasing adoption of insulin pens among diabetes patients. Short and fine needles result in less pain for the user, which is also the major factor driving the adoption of these devices. The pen devices are further subsegment into reusable insulin pen and disposable insulin pen. Factors such as fine disposable needles, dose-measuring dial, improved connectivity, accuracy and user experience are driving the insulin pen market. The insulin pumps is projected to lead the market of the market during the forecast period. Developing closed-loop insulin pump, wearable disposable insulin pump, as well as factors like growing use of tubeless patch pump for automated insulin delivery for diabetic care, are the factors contributing the insulin pump market growth.

By end user, the patients/home care is projected to lead the market of the insulin delivery devices industry during the forecast period

By end user, the insulin delivery devices market is broadly segmented into patients/home care and hospitals & clinics. Patients/ home care segment is projected to lead the global market in 2023. The high growth rate of this segment can be attributed to the greater focus on the training patients for effective use of devices for self administration of insulin, growing diabetic population and increasing diabetic healthcare expenditure.

North American region of the insulin delivery devices industry to witness significant growth from 2023 to 2028

On the basis of region, the insulin delivery devices market is divided into North America, Europe, Asia Pacific and Rest of world. In 2023, North America projected to lead market share of the market. Increasing diabetes healthcare expenditure, and the favorable reimbursement in the region are driving the growth of the market in North America.

Insulin Delivery Devices Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The prominent players operating in the global insulin delivery devices market are Embecta Corp. (Formerly Becton, Dickinson and Company Diabetes Care Business (US), Novo Nordisk A/S (Denmark), Medtronic (Ireland), Sanofi (France), Eli Lilly and Company (US), Ypsomed Holding AG (Switzerland), Tandem Diabetes Care (US), Insulet Corporation (US), Biocon Limited (India), Roche Diabetes Care (Switzerland), Owen Mumford (England), Mrdtrum Technologies Inc. (China), Terumo Corporation (Japan), Wockhardt (India), Cerur Corporation (Switzerland), EoFlow CO., Ltd. (South Korea), Hindustan Syringes & Medical Devices Ltd (India), Sooil Developments CO., Ltd (Korea), Sungshim Medical Co., Ltd. (South Korea), Vicentra B.V. (Netherland), Debiotech SA (Switzerland), Jiangsu Delfu Medical Device Co., Ltd (China), Haselmeier (Germany), Mannkind Corporation (US), HTL-Sterfa S.A. (Poland).

Scope of the Insulin Delivery Devices Industry

Report Metric

Details

Market Revenue Size in 2023

$30.8 billion

Projected Revenue Size by 2028

$46.2 billion

Industry Growth Rate

Poised to Grow at a CAGR of 8.5%

Market Driver

Growing prevalence of diabetic population

Market Opportunity

Increasing healthcare expenditure on diabetes care

This research study categorizes the global insulin delivery devices market to forecast revenue and analyze trends in each of the following submarkets:

By Type
  • Insulin Pens
    • Reusable Insulin Pens
    • Disposable Insulin Pens
  • Insulin Pumps
    • Tethered Insulin Pumps
    • Tubeless Insulin Pumps
  • Insulin Pen Needles
    • Standard Insulin Pen Needles
    • Safety Insulin Pen Needles
  • Insulin Syringes
  • Other Insulin Delivery Devices (insulin transdermal patches, insulin inhalers, insulin jet injectors, etc. )
By End User
  • Patients/Home Care
  • Hospitals & Clinics
By Region
  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe (RoE)
  • Asia Pacific
    • Japan
    • China
    • India
    • Rest of APAC (RoAPAC)
  • Rest of World

Recent Developments of Insulin Delivery Devices Industry

  • In 2023, Embecta Corp. opened a new global headquarters office at 300 Kimball Drive, Suite 300, IN Parsippany, N.J. The site is expected to be home to members of the leadership team, global support functions and North American commercial organization to develop and provide solutions that make life better for people coping with diabetes.
  • In 2023, Eli Lilly announced price reductions of 70% for its most prescribed insulins and an expansion of its Insulin Value Program that caps patients out-of-pocket cost at USD 35 or less per month.
  • In 2023, Novo Nordisk launched the first smart insulin pens NovoPen 6 and NovoPen Echo Plus available in the UK.
  • In 2022, Medtronic entered into a set of definitive agreements to acquire EOFlow Co. Ltd., a manufacturer of the EOPatch device- a tubeless, wearable and fully disposable insulin delivery device.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 20)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE 
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY CONSIDERED 
    1.5 LIMITATIONS 
    1.6 STAKEHOLDERS 
    1.7 SUMMARY OF CHANGES 
 
2 RESEARCH METHODOLOGY (Page No. - 25)
    2.1 RESEARCH DATA 
          FIGURE 1 INSULIN DELIVERY DEVICES MARKET: RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    FIGURE 2 PRIMARY SOURCES
                    2.1.2.1 Key data from primary sources
                                FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
                                FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER AND REGION
    2.2 MARKET SIZE ESTIMATION 
          FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2022)
          FIGURE 6 MARKET SIZE ESTIMATION: COMPANY-WISE REVENUE SHARE ANALYSIS (2022)
          FIGURE 7 INSULIN DELIVERY DEVICES MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2023–2028)
          FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS OF MARKET
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION 
          FIGURE 9 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ESTIMATION 
    2.5 STUDY ASSUMPTIONS 
    2.6 IMPACT OF RECESSION 
          TABLE 1 GLOBAL INFLATION RATE PROJECTIONS. 2021–2027 (%GROWTH)
 
3 EXECUTIVE SUMMARY (Page No. - 38)
    FIGURE 10 INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
    FIGURE 11 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 12 GEOGRAPHICAL SNAPSHOT OF MARKET
 
4 PREMIUM INSIGHTS (Page No. - 41)
    4.1 INSULIN DELIVERY DEVICES: MARKET OVERVIEW 
          FIGURE 13 INCREASING TECHNOLOGICAL ADVANCEMENTS IN INSULIN DELIVERY DEVICES TO DRIVE MARKET
    4.2 ASIA PACIFIC: MARKET, BY TYPE AND COUNTRY (2022) 
          FIGURE 14 INSULIN PENS SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2022
    4.3 INSULIN DELIVERY DEVICES INDUSTRY: GEOGRAPHICAL MIX 
          FIGURE 15 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
    4.4 MARKET: REGIONAL MIX (2023–2028) 
          FIGURE 16 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD (2023–2028)
    4.5 MARKET: DEVELOPED VS. DEVELOPING MARKETS 
          FIGURE 17 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD
 
5 MARKET OVERVIEW (Page No. - 45)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 18 INSULIN DELIVERY DEVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Growing prevalence of diabetic population
                                FIGURE 19 GLOBAL PREVALENCE OF DIABETES IN INDIVIDUALS AGED 20–79 YEARS, 2015–2021 (MILLIONS)
                                FIGURE 20 PROJECTION OF DIABETES FOR INDIVIDUALS AGED 20–79 YEARS, 2030-2045 (MILLIONS)
                                FIGURE 21 TOP TEN COUNTRIES WITH HIGHEST COUNT OF DIABETICS (20–79 YEARS), 2021 & 2045
                    5.2.1.2 Technological advancements in insulin delivery devices
                                FIGURE 22 ADVANCEMENTS IN INSULIN DELIVERY DEVICES
                    5.2.1.3 Government support and favorable reimbursement schemes to favor market growth
           5.2.2 RESTRAINTS
                    5.2.2.1 High costs and lack of reimbursement in developing countries
                    5.2.2.2 Needle anxiety in patients to affect growth of pen needles and syringes market
                    5.2.2.3 Oral insulin as alternative drug delivery method
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Increasing R&D activities and strategic partnerships
                    5.2.3.2 Increasing healthcare expenditure on diabetes care
                                FIGURE 23 TOTAL HEALTH EXPENDITURE ON DIABETES CARE, 2021–2045 (USD BILLION)
                    5.2.3.3 Advances in syringe and needle technology
                    5.2.3.4 Mandates pertaining to safety-engineered medical needles to encourage market growth
           5.2.4 CHALLENGES
                    5.2.4.1 Needlestick injuries and misuse of injection pens
                    5.2.4.2 Lack of interoperability among insulin delivery devices
    5.3 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 2 INSULIN DELIVERY DEVICES INDUSTRY: PORTER’S FIVE FORCES ANALYSIS
           5.3.1 INTENSITY OF COMPETITIVE RIVALRY
           5.3.2 BARGAINING POWER OF SUPPLIERS
           5.3.3 BARGAINING POWER OF BUYERS
           5.3.4 THREAT OF SUBSTITUTES
           5.3.5 THREAT OF NEW ENTRANTS
    5.4 REGULATORY ANALYSIS 
          TABLE 3 INDICATIVE LIST OF REGULATORY AUTHORITIES
           5.4.1 NORTH AMERICA
                    5.4.1.1 US
                                TABLE 4 US: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
                                FIGURE 24 FDA 510(K) APPROVAL PROCESS
                    5.4.1.2 Canada
           5.4.2 EUROPE
                                FIGURE 25 CE MARK APPROVAL PROCESS FOR INSULIN DELIVERY DEVICES
           5.4.3 ASIA PACIFIC
                    5.4.3.1 Japan
                                TABLE 5 JAPAN: CLASSIFICATION OF MEDICAL DEVICES AND REVIEWING BODY
                    5.4.3.2 China
                                TABLE 6 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
                    5.4.3.3 India
                                TABLE 7 INDIA: MEDICAL DEVICE CLASSIFICATION
                    5.4.3.4 Australia
                                FIGURE 26 SUMMARY OF APPROVAL, ACCESS, AND DISTRIBUTION PATHWAYS FOR NEW TECHNOLOGY USED FOR INSULIN DRUG DELIVERY DEVICES
           5.4.4 REST OF THE WORLD
    5.5 INDUSTRY INSIGHTS 
           5.5.1 GROWING DEMAND FOR HYBRID CLOSED-LOOP SYSTEMS/ARTIFICIAL PANCREAS DEVICE SYSTEMS
                    TABLE 8 HYBRID CLOSED-LOOP SYSTEMS: CURRENT MARKET SCENARIO
           5.5.2 SYNCHRONIZATION OF SMART INSULIN PENS WITH CGM SYSTEMS TO PROMOTE DIABETES DATA SHARING
                    TABLE 9 MAJOR SMART INSULIN PENS AVAILABLE GLOBALLY
           5.5.3 INCREASING NUMBER OF COLLABORATIONS AMONG STAKEHOLDERS
                    TABLE 10 INSULIN DELIVERY DEVICE MARKET: RECENT COLLABORATIONS
    5.6 REIMBURSEMENT SCENARIO 
          TABLE 11 INSULIN DELIVERY DEVICES: GLOBAL COVERAGE AND REIMBURSEMENT
           5.6.1 US
           5.6.2 CANADA
           5.6.3 UK
           5.6.4 AUSTRALIA
           5.6.5 OTHER COUNTRIES
    5.7 TECHNOLOGICAL ANALYSIS 
    5.8 KEY CONFERENCES & EVENTS, 2023–2024 
          TABLE 12 MARKET: DETAILED LIST OF CONFERENCES & EVENTS
    5.9 PRICING ANALYSIS 
           5.9.1 AVERAGE SELLING PRICE OF KEY PLAYERS, BY PRODUCT
                    TABLE 13 AVERAGE SELLING PRICE OF INSULIN PENS, BY KEY PLAYER
                    TABLE 14 AVERAGE SELLING PRICE OF INSULIN PUMPS, BY KEY PLAYER
    5.10 PATENT ANALYSIS 
           FIGURE 27 PATENT PUBLICATION TRENDS (JANUARY 2011–MAY 2023)
           5.10.1 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
                     FIGURE 28 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTES) FOR INSULIN DELIVERY DEVICES PATENTS (JANUARY 2011–MAY 2023)
                     FIGURE 29 TOP APPLICANT COUNTRIES/REGIONS FOR INSULIN DELIVERY DEVICES (JANUARY 2011–MAY 2023)
    5.11 VALUE CHAIN ANALYSIS 
           FIGURE 30 MARKET: VALUE CHAIN ANALYSIS
    5.12 ECOSYSTEM MARKET MAP 
           FIGURE 31 INSULIN DELIVERY DEVICE MARKET: ECOSYSTEM MAPPING
    5.13 USE CASES 
           TABLE 15 T:SLIM X2 INSULIN PUMPS TO OFFER CONTINUED IMPROVEMENTS IN FUNCTIONALITY, SAFETY, AND WEARABILITY OF PUMPS
           TABLE 16 AUTOMATED AND SMART INSULIN DELIVERY DEVICE FOR DIABETES CARE
           TABLE 17 CONTRIBUTION OF SMART INSULIN PEN IN LIGHTENING DIABETES MANAGEMENT LOAD
    5.14 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF INSULIN DELIVERY DEVICES
           5.14.2 BUYING CRITERIA FOR INSULIN DELIVERY DEVICES
                     FIGURE 33 KEY BUYING CRITERIA FOR END USERS
 
6 INSULIN DELIVERY DEVICES MARKET, BY TYPE (Page No. - 80)
    6.1 INTRODUCTION 
          TABLE 18 INSULIN DELIVERY DEVICES INDUSTRY, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 19 MARKET, BY TYPE, 2021–2028 (THOUSAND UNITS)
    6.2 INSULIN PENS 
           6.2.1 ADVANCED AND CONVENIENT SOLUTIONS FOR INSULIN ADMINISTRATION TO DRIVE MARKET
                    TABLE 20 INSULIN PENS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 21 INSULIN PENS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 22 INSULIN PENS MARKET, BY REGION, 2021–2028 (THOUSAND UNITS)
           6.2.2 REUSABLE INSULIN PENS
                    6.2.2.1 Technology innovations to boost growth
                                TABLE 23 REUSABLE INSULIN PENS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
           6.2.3 DISPOSABLE INSULIN PENS
                    6.2.3.1 Shift toward eco-friendly environment to restrain growth of market during forecast period
                                TABLE 24 DISPOSABLE INSULIN PENS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    6.3 INSULIN PUMPS 
           6.3.1 NEWER AND MORE REFINED TECHNOLOGY TO DRIVE INSULIN PUMPS MARKET
                    TABLE 25 INSULIN PUMPS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 26 INSULIN PUMPS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 27 INSULIN PUMPS MARKET, BY REGION, 2021–2028 (THOUSAND UNITS)
           6.3.2 TETHERED INSULIN PUMPS
                    6.3.2.1 Increasing collaborations and partnerships between companies to develop integrated CGM systems to drive market
                                TABLE 28 TETHERED INSULIN PUMPS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
           6.3.3 TUBELESS INSULIN PUMPS
                    6.3.3.1 Use of artificial intelligence and technological advancements to boost market
                                TABLE 29 TUBELESS INSULIN PUMPS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    6.4 INSULIN PEN NEEDLES 
          TABLE 30 INSULIN PEN NEEDLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 31 INSULIN PEN NEEDLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 32 INSULIN PEN NEEDLES MARKET, BY REGION, 2021–2028 (THOUSAND UNITS)
           6.4.1 STANDARD INSULIN PEN NEEDLES
                    6.4.1.1 Affordability of standard insulin pen needles over safety pen needles to propel growth
                                TABLE 33 STANDARD INSULIN PEN NEEDLES OFFERED BY KEY PLAYERS
                                TABLE 34 STANDARD INSULIN PEN NEEDLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
           6.4.2 SAFETY INSULIN PEN NEEDLES
                    6.4.2.1 Reducing chances of infection and accidental pricking to drive market
                                TABLE 35 SAFETY INSULIN PEN NEEDLES OFFERED BY KEY PLAYERS
                                TABLE 36 SAFETY INSULIN PEN NEEDLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    6.5 INSULIN SYRINGES 
           6.5.1 SAFETY CONCERNS AND INCREASING AWARENESS OF AFFORDABLE ALTERNATIVES TO RESTRAIN GROWTH
                    TABLE 37 INSULIN SYRINGES MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 38 INSULIN SYRINGES MARKET, BY REGION, 2021–2028 (THOUSAND UNITS)
    6.6 OTHER INSULIN DELIVERY DEVICES 
          TABLE 39 OTHER MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 40 OTHER MARKET, BY REGION, 2021–2028 (THOUSAND UNITS)
 
7 INSULIN DELIVERY DEVICES MARKET, BY END USER (Page No. - 100)
    7.1 INTRODUCTION 
          TABLE 41 INSULIN DELIVERY DEVICES INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
    7.2 PATIENTS/HOME CARE 
           7.2.1 INCREASING AFFORDABILITY OF SELF-MONITORING SYSTEMS AND INSULIN DELIVERY DEVICES TO FUEL GROWTH
                    TABLE 42 MARKET FOR PATIENTS/HOME CARE, BY COUNTRY, 2021–2028 (USD MILLION)
    7.3 HOSPITALS & CLINICS 
           7.3.1 RISING DEMAND FOR POINT-OF-CARE TESTING IN HOSPITALS TO BOOST MARKET
                    TABLE 43 MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2021–2028 (USD MILLION)
 
8 INSULIN DELIVERY DEVICES MARKET, BY REGION (Page No. - 104)
    8.1 INTRODUCTION 
          FIGURE34 MARKET: GEOGRAPHIC SNAPSHOT
          TABLE 44 MARKET, BY REGION, 2021–2028 (USD MILLION)
    8.2 NORTH AMERICA 
           8.2.1 NORTH AMERICA: RECESSION IMPACT
                    FIGURE35 NORTH AMERICA: INSULIN DELIVERY DEVICES MARKET SNAPSHOT
                    TABLE 45 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 46 NORTH AMERICA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 47 NORTH AMERICA: INSULIN PENS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 48 NORTH AMERICA: INSULIN PUMPS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 49 NORTH AMERICA: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                    TABLE 50 NORTH AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
           8.2.2 US
                    8.2.2.1 Rising prevalence of diabetes and favorable reimbursement scenario to drive market
                    8.2.2.2 Growing venture capital investments and issuance of IPOs to propel market growth
                                TABLE 51 US: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 52 US: INSULIN PENS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 53 US: INSULIN PUMPS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 54 US: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 55 US: MARKET, BY END USER, 2021–2028 (USD MILLION)
           8.2.3 CANADA
                    8.2.3.1 High prevalence of diabetes and favorable reimbursement for insulin delivery devices to boost market
                                TABLE 56 CANADA: ELIGIBILITY FOR INSULIN PUMPS AND SUPPLIES FOR TYPE I DIABETES, APRIL 2021
                    8.2.3.2 Regulations for usage of safety-engineered needles to drive market
                                TABLE 57 CANADA: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 58 CANADA: INSULIN PENS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 59 CANADA: INSULIN PUMPS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 60 CANADA: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 61 CANADA: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
    8.3 EUROPE 
           8.3.1 EUROPE: RECESSION IMPACT
                    8.3.1.1 EU’s directive on prevention of sharps injuries in hospitals and healthcare sector to drive market
                                TABLE 62 EUROPE: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 63 EUROPE: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 64 EUROPE: INSULIN PENS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 65 EUROPE: INSULIN PUMPS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 66 EUROPE: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 67 EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
           8.3.2 GERMANY
                    8.3.2.1 High prevalence of diabetes and favorable reimbursement for insulin devices to propel market
                                TABLE 68 GERMANY: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 69 GERMANY: INSULIN PENS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 70 GERMANY: INSULIN PUMPS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 71 GERMANY: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 72 GERMANY: MARKET, BY END USER, 2021–2028 (USD MILLION)
           8.3.3 UK
                    8.3.3.1 Role of Diabetes UK in research and diabetes care to boost market
                    8.3.3.2 Insulin pump penetration to boost market
                                TABLE 73 UK: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 74 UK: INSULIN PENS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 75 UK: INSULIN PUMPS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 76 UK: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 77 UK: INSULIN DELIVERY DEVICES INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
           8.3.4 FRANCE
                    8.3.4.1 High insurance coverage and increasing affordability to drive market
                                TABLE 78 FRANCE: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 79 FRANCE: INSULIN PENS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 80 FRANCE: INSULIN PUMPS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 81 FRANCE: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 82 FRANCE: MARKET, BY END USER, 2021–2028 (USD MILLION)
           8.3.5 ITALY
                    8.3.5.1 Regional variations in terms of coverage and benefits to hinder market growth
                                TABLE 83 ITALY: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 84 ITALY: INSULIN PENS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 85 ITALY: INSULIN PUMPS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 86 ITALY: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 87 ITALY: MARKET, BY END USER, 2021–2028 (USD MILLION)
           8.3.6 SPAIN
                    8.3.6.1 Regulations for mandatory use of safety needles and increase in diabetic population to propel market
                                TABLE 88 SPAIN: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 89 SPAIN: INSULIN PENS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 90 SPAIN: INSULIN PUMPS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 91 SPAIN: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 92 SPAIN: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
           8.3.7 REST OF EUROPE
                    8.3.7.1 Strong presence of major insulin delivery device manufacturers to drive market
                                TABLE 93 INDICATIVE LIST OF COMPANIES HEADQUARTERED IN REST OF EUROPE
                                FIGURE 36 TOP FIVE COUNTRIES WITH HIGHEST NUMBER OF DIABETICS (20–79 YEARS) IN MILLIONS
                                TABLE 94 REST OF EUROPE: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 95 REST OF EUROPE: INSULIN PENS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 96 REST OF EUROPE: INSULIN PUMPS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 97 REST OF EUROPE: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 98 REST OF EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
    8.4 ASIA PACIFIC 
           8.4.1 ASIA PACIFIC: RECESSION IMPACT
                    FIGURE 37 ASIA PACIFIC: INSULIN DELIVERY DEVICES MARKET SNAPSHOT
                    8.4.1.1 High diabetes incidence and population in Asia Pacific to boost market
                                TABLE 99 ASIA PACIFIC: DIABETES PREVALENCE, BY COUNTRY
                    8.4.1.2 Partnerships among global and local players in Asia Pacific to drive market
                                TABLE 100 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                                TABLE 101 ASIA PACIFIC: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 102 ASIA PACIFIC: INSULIN PENS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 103 ASIA PACIFIC: INSULIN PUMPS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 104 ASIA PACIFIC: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 105 ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
           8.4.2 JAPAN
                    8.4.2.1 High adoption of insulin pens and approval of injectable insulin to propel growth
                                TABLE 106 JAPAN: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 107 JAPAN: INSULIN PENS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 108 JAPAN: INSULIN PUMPS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 109 JAPAN: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 110 JAPAN: INSULIN DELIVERY DEVICES INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
           8.4.3 CHINA
                    8.4.3.1 Sharp increase in diabetes in past decade and government support to drive market
                                TABLE 111 CHINA: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 112 CHINA: INSULIN PENS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 113 CHINA: INSULIN PUMPS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 114 CHINA: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 115 CHINA: MARKET, BY END USER, 2021–2028 (USD MILLION)
           8.4.4 INDIA
                    8.4.4.1 Government initiatives to promote domestic manufacture of medical devices to drive market
                                TABLE 116 INDIA: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 117 INDIA: INSULIN PENS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 118 INDIA: INSULIN PUMPS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 119 INDIA: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 120 INDIA: MARKET, BY END USER, 2021–2028 (USD MILLION)
           8.4.5 REST OF ASIA PACIFIC
                    8.4.5.1 Vietnam: Large diabetic population to boost market
                    8.4.5.2 Australia: Government initiatives to broaden patient access to diabetes products
                                TABLE 121 ASIA PACIFIC: INSULIN DELIVERY DEVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 122 ASIA PACIFIC: INSULIN PENS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 123 ASIA PACIFIC: INSULIN PUMPS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 124 ASIA PACIFIC: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 125 ASIA PACIFIC: INSULIN DELIVERY DEVICES MARKET, BY END USER, 2021–2028 (USD MILLION)
    8.5 REST OF THE WORLD 
           8.5.1 REST OF THE WORLD: RECESSION IMPACT
                    8.5.1.1 Increasing diabetic population to propel market
                                FIGURE 38 AFRICA: TOP FIVE COUNTRIES WITH HIGHEST NUMBER OF DIABETICS (20–79 YEARS)
                    8.5.1.2 Favorable government policies and increasing prevalence of diabetic population to drive market
                                FIGURE 39 COUNT OF DIABETICS (20–79 YEARS) IN LATIN AMERICA REGION: TOP FIVE COUNTRIES
                                TABLE 126 REST OF THE WORLD: MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 127 REST OF THE WORLD: INSULIN PENS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 128 REST OF THE WORLD: INSULIN PUMPS MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 129 REST OF THE WORLD: INSULIN PEN NEEDLES MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                TABLE 130 REST OF THE WORLD: MARKET, BY END USER, 2021–2028 (USD MILLION)
 
9 COMPETITIVE LANDSCAPE (Page No. - 155)
    9.1 OVERVIEW 
    9.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 
          TABLE 131 INSULIN DELIVERY DEVICES MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
    9.3 MARKET SHARE ANALYSIS 
          FIGURE40 MARKET SHARE ANALYSIS FOR INSULIN PENS, BY KEY PLAYERS, 2022
          FIGURE41 MARKET SHARE ANALYSIS FOR INSULIN PUMPS, BY KEY PLAYERS, 2022
          FIGURE42 MARKET SHARE ANALYSIS FOR INSULIN PEN NEEDLES, BY KEY PLAYERS, 2022
          FIGURE43 MARKET SHARE ANALYSIS FOR INSULIN SYRINGES, BY KEY PLAYERS, 2022
    9.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 
          FIGURE44 REVENUE ANALYSIS OF KEY PLAYERS (2020–2022)
    9.5 MARKET RANKING ANALYSIS 
          FIGURE45 INSULIN DELIVERY DEVICES INDUSTRY RANKING, BY KEY PLAYERS, 2022
    9.6 COMPANY EVALUATION QUADRANT: KEY PLAYERS 
           9.6.1 STARS
           9.6.2 EMERGING LEADERS
           9.6.3 PERVASIVE PLAYERS
           9.6.4 PARTICIPANTS
                    FIGURE46 MARKET: COMPETITIVE LEADERSHIP MAPPING (2022)
    9.7 COMPANY EVALUATION QUADRANT: START-UPS & SMES 
           9.7.1 PROGRESSIVE COMPANIES
           9.7.2 DYNAMIC COMPANIES
           9.7.3 STARTING BLOCKS
           9.7.4 RESPONSIVE COMPANIES
                    FIGURE47 MARKET: COMPANY EVALUATION MATRIX FOR START-UPS (2022)
    9.8 COMPANY FOOTPRINT OF PLAYERS IN MARKET 
          TABLE 132 MARKET: COMPANY FOOTPRINT (2022)
           9.8.1 TYPE FOOTPRINT
                    TABLE 133 MARKET: TYPE FOOTPRINT (2022)
           9.8.2 REGIONAL FOOTPRINT
                    TABLE 134 MARKET: REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS (2022)
    9.9 COMPETITIVE SCENARIO 
           9.9.1 PRODUCT LAUNCHES
                    TABLE 135 PRODUCT LAUNCHES, JANUARY 2019–JUNE 2023
           9.9.2 DEALS
                    TABLE 136 DEALS, JANUARY 2019–JUNE 2023
           9.9.3 OTHER DEVELOPMENTS
                    TABLE 137 OTHER DEVELOPMENTS, JANUARY 2019–JUNE 2023
 
10 COMPANY PROFILES (Page No. - 171)
     10.1 KEY PLAYERS 
(Business Overview, Products/Solutions/Services offered, Recent Developments, MnM View)*
             10.1.1 EMBECTA CORP. (FORMERLY BECTON, DICKINSON AND COMPANY DIABETES CARE BUSINESS)
                        TABLE 138 EMBECTA CORP.: COMPANY OVERVIEW
                        FIGURE 48 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2022)
             10.1.2 NOVO NORDISK A/S
                        TABLE 139 NOVO NORDISK A/S: COMPANY OVERVIEW
                        FIGURE 49 NOVO NORDISK A/S: COMPANY SNAPSHOT (2022)
             10.1.3 MEDTRONIC PLC
                        TABLE 140 MEDTRONIC PLC: COMPANY OVERVIEW
                        FIGURE 50 MEDTRONIC PLC: COMPANY SNAPSHOT (2022)
             10.1.4 SANOFI
                        TABLE 141 SANOFI: COMPANY OVERVIEW
                        FIGURE 51 SANOFI: COMPANY SNAPSHOT (2022)
             10.1.5 LILLY
                        TABLE 142 LILLY: COMPANY OVERVIEW
                        FIGURE 52 LILLY: COMPANY SNAPSHOT (2022)
             10.1.6 YPSOMED HOLDING AG
                        TABLE 143 YPSOMED HOLDING AG: COMPANY OVERVIEW
                        FIGURE 53 YPSOMED HOLDING AG: COMPANY SNAPSHOT (2023)
             10.1.7 TANDEM DIABETES CARE, INC.
                        TABLE 144 TANDEM DIABETES CARE, INC.: COMPANY OVERVIEW
                        FIGURE 54 TANDEM DIABETES CARE, INC.: COMPANY SNAPSHOT (2022)
             10.1.8 INSULET CORPORATION
                        TABLE 145 INSULET CORPORATION: COMPANY OVERVIEW
                        FIGURE 55 INSULET CORPORATION: COMPANY SNAPSHOT (2022)
             10.1.9 BIOCON LIMITED
                        TABLE 146 BIOCON LIMITED: COMPANY OVERVIEW
                        FIGURE 56 BIOCON LIMITED: COMPANY SNAPSHOT (2022)
             10.1.10 ROCHE DIABETES CARE
                        TABLE 147 F. HOFFMANN-LA ROCHE: COMPANY OVERVIEW
                        FIGURE 57 F. HOFFMANN-LA ROCHE: COMPANY SNAPSHOT (2022)
             10.1.11 OWEN MUMFORD
                        TABLE 148 OWEN MUMFORD: COMPANY OVERVIEW
             10.1.12 MEDTRUM TECHNOLOGIES INC.
                        TABLE 149 MEDTRUM TECHNOLOGIES INC.: COMPANY OVERVIEW
             10.1.13 TERUMO CORPORATION
                        TABLE 150 TERUMO CORPORATION: COMPANY OVERVIEW
                        FIGURE 58 TERUMO CORPORATION: COMPANY SNAPSHOT (2021)
             10.1.14 WOCKHARDT
                        TABLE 151 WOCKHARDT: COMPANY OVERVIEW
                        FIGURE 59 WOCKHARDT: COMPANY SNAPSHOT (2021)
*Details on Business Overview, Products/Solutions/Services offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
     10.2 OTHER PLAYERS 
             10.2.1 CEQUR CORPORATION
             10.2.2 EOFLOW CO., LTD.
             10.2.3 HINDUSTAN SYRINGES & MEDICAL DEVICES LTD
             10.2.4 SOOIL DEVELOPMENTS CO., LTD
             10.2.5 SUNGSHIM MEDICAL CO., LTD.
             10.2.6 VICENTRA B.V.
             10.2.7 DEBIOTECH SA
             10.2.8 JIANGSU DELFU MEDICAL DEVICE CO., LTD
             10.2.9 HASELMEIER
             10.2.10 MANNKIND CORPORATION
             10.2.11 HTL-STREFA S.A.
 
11 APPENDIX (Page No. - 220)
     11.1 DISCUSSION GUIDE 
     11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     11.3 CUSTOMIZATION OPTIONS 
     11.4 RELATED REPORTS 
     11.5 AUTHOR DETAILS 

This study involved four major activities in estimating the size of the insulin delivery devices market. Exhaustive secondary research was done to collect information on the market, peer market, and parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across value chains through primary research. The bottom-up approach was employed to estimate the overall market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and sub-segments.

Secondary Research

The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Some non-exclusive secondary sources include the World Health Organization (WHO), American Diabetes Association (ADA), American, Association of Clinical Endocrinologists (AACE), American Association of Diabetes Educators (AADE), American Academy of Pediatrics (AAP), Asian Association for the Study of Diabetes (AASD), Brazilian Diabetes Association (BDA), Latin American Diabetes Association (ALAD), National Association of Diabetes Care, Brazil (ANAD), Juvenile Diabetes Research Foundation (JDRF), International Diabetes Federation (IDF), Diabetes Research Institute Foundation (DRI) Annual Reports, SEC Filings, Investor Presentations, Journals, Publications from Government Sources and Professional Associations, Expert Interviews, and MarketsandMarkets Analysis.

Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the clinical decision support system market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include suppliers, distributors, CEOs, vice presidents, marketing and sales directors, business development managers, and technology and innovation directors of types of insulin delivery device providers. Primary sources from the demand side include industry experts such as homecare providers, healthcare professionals, diabetes patients, payers, and other related key opinion leaders.

Breakdown of Primary Interviews by supply side

Insulin Delivery Devices Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Note 1: Companies are classified into tiers based on their total revenue. As of 2021: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.

Note 2: C-level executives include CEOs, COOs, CTOs, and VPs. 

Note 3: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

Market Size Estimation

The research methodology used to estimate the market size includes the following details:

Total Market Size: The total size of the insulin delivery devices market was arrived at after data triangulation from different approaches, as mentioned below. After completing each approach, the weighted average of the various approaches was taken based on the level of assumptions used in each approach.

REVENUE SHARE ANALYSIS

  • The revenues of individual companies were gathered from public sources and databases.
  • Shares of the insulin delivery devices businesses of leading players were gathered from secondary sources to the extent available. In certain cases, shares of the insulin delivery devices market have been ascertained after a detailed analysis of various parameters, including product portfolios, market positioning, selling price, geographic reach, and strength.
  • Individual shares or revenue estimates were validated through expert interviews.

Insulin Delivery Devices Market Size, and Share

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.

Market Definition

Insulin delivery devices are medical devices designed to administer insulin, a hormone used in the management of diabetes, into the body. These devices are primarily used by individuals with diabetes who require insulin therapy to regulate their blood sugar levels. Insulin pens, pumps, pen needles, and syringes are the most widely used delivery devices

Key Stakeholders

  • Insulin delivery device manufacturers, vendors, and distributors
  • Group purchasing organizations (GPOs)
  • Original equipment manufacturers (OEMs)
  • Physicians/Diabetologists
  • Homecare providers
  • Hospitals and clinics
  • Contract research organizations (CROs)
  • Research institutes and government organizations
  • Market research and consulting firms
  • Contract manufacturing organizations (CMOs)
  • Venture capitalists
  • Senior Management
  • Purchase & Finance Departments
  • Patients

Report Objectives

  • To define, measure, and describe the global insulin delivery devices market on the basis of type, end user, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, challenges, and opportunities)
  • To analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of market segments with respect to four main regions, namely, North America, Europe, Asia Pacific, and RoW
  • To strategically analyze the market structure and profile key players in the global insulin delivery devices market and comprehensively analyze their core competencies
  • To track and analyze company developments such as partnerships, agreements, and collaborations; expansions; joint ventures; and product launches in the insulin delivery devices market

Available Customizations

MarketsandMarkets offers the following customizations for this market report:

  • Product matrix, which gives a detailed comparison of the product portfolios of the top companies
  • Further breakdown of the Rest of the Asia Pacific insulin delivery devices  market into Australia, New Zealand, and other countries
  • Further breakdown of the Rest of Europe insulin delivery devices  market into Italy, Spain, Belgium, Russia, the Netherlands, Switzerland, and other countries
  • Detailed analysis and profiling of additional market players (up to 5)
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
MD 5192
Published ON
Jul, 2023
REQUEST FREE SAMPLE REPORT
Choose License Type
BUY NOW
Inquire Before Buying
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Insulin Delivery Devices Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status
Website Feedback